Drug Trial Radar · NCT01101035
Cardiovascular Safety of Febuxostat and Allopurinol in Participants With Gout and Cardiovascular Comorbidities (CARES)
Last checked: Nov 20, 2026Latest source record: Jun 14, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
6,198
Actual
Start
Apr 23, 2010
Primary completion
May 15, 2017
Study completion Jul 18, 2017
Sponsor
- Lead sponsor
- TakedaTakeda (TAK)
- Sponsor type
- Industry
- First posted
- Apr 9, 2010
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to see whether subjects with gout who receive febuxostat or allopurinol for up to 9 years have a higher rate of serious heart and blood vessel complications (major cardiovascular events).
Conditions
- Cardiovascular Disease
Interventions
FebuxostatDrug
Febuxostat tablets
AllopurinolDrug
Allopurinol tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Primary Major Adverse Cardiovascular Events (MACE) Composite (75% Interim Analysis)Time frame: Up to last dose of study drug (approximately 83 months)
- Percentage of Participants With Primary MACE Composite (Final Analysis)Time frame: Up to last dose of study drug (approximately 83 months)
Locations
203 sites in 2 countries. Site status is shown where the registry gives one.
Site not named
Decatur, Georgia
Site not named
Dunwoody, Georgia
Site not named
Marietta, Georgia
Site not named
Norcross, Georgia
Site not named
Roswell, Georgia
Site not named
Suwanee, Georgia
Site not named
Waycross, Georgia
Site not named
Honolulu, Hawaii
Site not named
Boise, Idaho
Site not named
Coeur d'Alene, Idaho
Site not named
Nampa, Idaho
Site not named
Addison, Illinois
Site not named
Arlington Heights, Illinois
Site not named
Evanston, Illinois
Site not named
Evergreen Park, Illinois
Site not named
Flossmoor, Illinois
Site not named
Melrose Park, Illinois
Site not named
Morton, Illinois
Site not named
Naperville, Illinois
Site not named
Quincy, Illinois
Site not named
Rockford, Illinois
Site not named
Bloomington, Indiana
Site not named
Brownsburg, Indiana
Site not named
Lafayette, Indiana
Site not named
Valparaiso, Indiana
Site not named
Iowa City, Iowa
Site not named
Lenexa, Kansas
Site not named
Overland Park, Kansas
Site not named
Topeka, Kansas
Site not named
Wichita, Kansas
Site not named
Elizabethtown, Kentucky
Site not named
Lexington, Kentucky
Site not named
Owensboro, Kentucky
Site not named
Paducah, Kentucky
Site not named
Mer Rouge, Louisiana
Site not named
Monroe, Louisiana
Site not named
Shreveport, Louisiana
Site not named
Biddeford, Maine
Site not named
Rockport, Maine
Site not named
Baltimore, Maryland
Showing 40 of 203 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.